Identification of interleukin-6 promoter polymorphisms in the Chinese Han population and their functional significance*
- 1 May 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 36 (5) , 1437-1443
- https://doi.org/10.1097/ccm.0b013e31816a0adb
Abstract
Objective: Interleukin-6 (IL-6) is a pivotal cytokine in both innate and adaptive immunity. Several polymorphisms in the IL-6 promoter have been reported in Western populations. However, little is known about their occurrence in the Chinese population. The functionality of IL-6 promoter polymorphisms remains controversial. Design: Genetic, functional, and association studies. Setting: National key laboratory of trauma and departments of traumatic surgery in two teaching hospitals. Subjects: A total of 348 healthy blood donors and 105 patients with major trauma. Interventions: None. Measurements and Main Results: Identification of polymorphisms in the IL-6 promoter was performed using sequencing and restriction fragment length polymorphism methods. Their functionality was assessed by observation of transcription activity, IL-6 production, and their clinical relevance in 105 patients with major trauma. Only one variant (C-572G) was identified in IL-6 promoter in Chinese Han population. This polymorphism was associated with IL-6 production by peripheral leukocytes in response to ex vivo lipopolysaccharide stimulation in an allele-dose-dependent effect. The C→G variation at position -572 could reduce transcriptional activity of the IL-6 promoter as shown in both U-937 and K562 cell lines. Moreover, the -572 polymorphism was associated with lower risk of sepsis in major trauma patients. Conclusions: The -572 polymorphism, a unique variation in the IL-6 promoter in the Chinese Han population, may be used as a relevant risk estimate for sepsis in trauma patients.Keywords
This publication has 47 references indexed in Scilit:
- Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction*Critical Care Medicine, 2006
- Inhibition of IL-1, IL-6, and TNF-α in immune-mediated inflammatory diseasesSpringer Seminars in Immunopathology, 2006
- Interleukin-6: discovery of a pleiotropic cytokineArthritis Research & Therapy, 2006
- Interleukin-6 and rheumatic diseasesArthritis Research & Therapy, 2006
- Interleukin-6: a new therapeutic targetArthritis Research & Therapy, 2006
- GENETIC POLYMORPHISMS AND SEPSISShock, 2005
- Role of Interleukin-6 in Mortality from and Physiologic Response to SepsisInfection and Immunity, 2005
- Association of an allelic variant of interleukin-6 with subclinical carotid atherosclerosis in an Australian community populationEuropean Heart Journal, 2003
- Cytokine gene polymorphisms in multifactorial diseases: gateways to novel targets for immunotherapy?Trends in Pharmacological Sciences, 2003
- Effect of the interleukin-6 promoter polymorphism (−174 G/C) on the incidence and outcome of sepsisCritical Care Medicine, 2002